151 related articles for article (PubMed ID: 38291158)
1. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.
Ji J; Zhou C; Yan LL; Ma Y; Xu C; Wang FA; Zhou WZ; Lv PH
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):299-309. PubMed ID: 38291158
[TBL] [Abstract][Full Text] [Related]
2. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Zhu HD; Li HL; Huang MS; Yang WZ; Yin GW; Zhong BY; Sun JH; Jin ZC; Chen JJ; Ge NJ; Ding WB; Li WH; Huang JH; Mu W; Gu SZ; Li JP; Zhao H; Wen SW; Lei YM; Song YS; Yuan CW; Wang WD; Huang M; Zhao W; Wu JB; Wang S; Zhu X; Han JJ; Ren WX; Lu ZM; Xing WG; Fan Y; Lin HL; Zhang ZS; Xu GH; Hu WH; Tu Q; Su HY; Zheng CS; Chen Y; Zhao XY; Fang ZT; Wang Q; Zhao JW; Xu AB; Xu J; Wu QH; Niu HZ; Wang J; Dai F; Feng DP; Li QD; Shi RS; Li JR; Yang G; Shi HB; Ji JS; Liu YE; Cai Z; Yang P; Zhao Y; Zhu XL; Lu LG; Teng GJ;
Signal Transduct Target Ther; 2023 Feb; 8(1):58. PubMed ID: 36750721
[TBL] [Abstract][Full Text] [Related]
5. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
[TBL] [Abstract][Full Text] [Related]
7. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
[TBL] [Abstract][Full Text] [Related]
8. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
9. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.
Yuan L; Feng J; Zhang Y; Lu C; Xu L; Liang C; Liu Z; Mao F; Xiang Y; Wang W; Wang K; Cheng S
Eur J Surg Oncol; 2023 Jul; 49(7):1226-1233. PubMed ID: 36739252
[TBL] [Abstract][Full Text] [Related]
12. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.
Marinelli B; Kim E; D'Alessio A; Cedillo M; Sinha I; Debnath N; Kudo M; Nishida N; Saeed A; Hildebrand H; Kaseb AO; Abugabal YI; Pillai A; Huang YH; Khan U; Muzaffar M; Naqash AR; Patel R; Fischman A; Bishay V; Bettinger D; Sung M; Ang C; Schwartz M; Pinato DJ; Marron T
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710293
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
15. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Gao B; Yang F; Zheng D; Hu S; Liu J; Liu H; Liu Y; Liu L; Wang R; Zhao Y; Cui C; Fang C; Yang J; Su S; Han Y; Yang X; Li B
J Hepatocell Carcinoma; 2023; 10():2265-2276. PubMed ID: 38107541
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
18. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
19. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
